Table 1.
Study | Number of implants | Follow-up | Age | M/F | Glenoid | Approach | Indications | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Authors, year | Implant | Poss. COI | Total | TSA | HA | Mean, mn | Range, mn | Mean | Range | Male % | Poly/MB | DP/AS | Prim. OA | Pt. OA | ON | CTA | RA | Instab. | Other |
Aibinder et al, 201927 | Sidus | Yes | 170 | 170 | 24.0 | 62.0 | 33–81 | 51 | Poly | DP | 100% | ||||||||
Athwal et al, 201942 | Sidus | Yes | 86 | 86 | 24.0 | 61.0 | 33–81 | 58 | Poly | DP | 93% | 7% | |||||||
Ballas et al, 20166 | TESS | Yes | 27 | 17 | 10 | 43.5 | 24–80 | 60.0 | 37–83 | 33 | Poly | DP* | 100% | ||||||
Beck et al, 201828 | TESS | No | 31 | 31 | 94.7 | 76–124 | 66.7 | 34–82 | 38 | Poly/MB | DP | 65% | 10%† | 25% | |||||
Bell and Coghlan, 201455 | Affinis | No | 12 | 12 | 24.0 | 65.9 | 49–76 | 50 | Poly | DP | 100% | ||||||||
Bell et al, 201925 | Affinis | Yes | 23 | 23 | 24.0 | 67.5 | 49–79 | 57 | Poly | DP | 100% | ||||||||
Berth and Pap, 20139 | TESS | No | 41 | 41 | 30.8 | 24–43 | 67.2 | 45–78 | 34 | Poly | DP | 100% | |||||||
Brunner et al, 201230 | Eclipse | Yes | 234 | 119 | 115 | 23.2 | 2–69 | 61.5 | 32–87 | 50 | Poly/MB | DP | 44% | 31% | 3% | 1% | 7% | 13% | 2% |
Bülhoff et al, 201931 | TESS | No | 38 | 28 | 10 | 37.1 | 24–72 | 66.4 | 55–81 | 53 | ns | AS | 100% | ||||||
Churchill et al, 201632 | Simpliciti | Yes | 149 | 149 | 24.0 | 66.0 | 37–84 | 72 | Poly | DP | 96% | 4% | |||||||
Collin et al, 201733 | Simpliciti | ND | 47 | 40 | 7 | 35.0 | 24–48 | 63.0 | 39–78 | 43 | ns | DP | 62% | 26% | 13% | ||||
Gallacher et al, 201834 | Eclipse | No | 100 | 100 | 35.4 | 24–76 | 71.0 | 44–90 | 42 | ns | DP | 100% | |||||||
Habermeyer et al, 201535 | Eclipse | Yes | 78 | 39 | 39 | 72.9 | 60–100 | 57.8 | 36–84 | 50 | Poly/MB | DP | 50% | 33% | 4% | 10% | 3% | ||
Hawi et al, 201736 | Eclipse | Yes | 49 | 17 | 32 | 108.0 | 90–127 | 56.0 | 21–81 | 51 | Poly/MB | DP | 14% | 49% | 4% | 14% | 6% | ||
Heuberer et al, 20188 | Eclipse | Yes | 73 | 33 | 40 | 58.1 | 48–78 | 67.6 | 40–84 | 33 | Poly | DP | 81% | 12% | 5% | 1% | |||
Huguet et al, 201037 | TESS | Yes | 63 | 19 | 44 | 36.0 | 36–51 | 64.5 | 52–76 | 46 | Poly/MB | DP | 86%* | 14% | |||||
Johansson et al, 201749 | Eclipse | No | 102 | 92 | 10 | 25.2 | 1–68 | 63.9 | 65 | Poly | DP | ND | |||||||
Jordan et al, 201941 | Affinis | Yes | 35 | 24 | 11 | 24.0 | 12–67 | 65.7 | 32–88 | 8 | Poly | DP/AS | 46% | 4% | 50% | ||||
Krukenberg et al, 201838 | Sidus | Yes | 105 | 73 | 32 | 24.0 | 64.0 | 40–79 | 50 | Poly/MB | DP | 100% | |||||||
Moursy et al, 201940 | Eclipse | No | 23 | 2 | 21 | 90.8 | 59.9 | Poly | DP | 65% | 13% | 9% | 4% | 9% | |||||
Razmjou et al, 201323 | TESS | No | 17 | 17 | 24.0 | 69.0 | 47 | Poly | DP | 100% | |||||||||
Spranz et al, 201726 | TESS | No | 12 | 12 | 51.6 | 32–73 | 74.0 | 64–79 | 44 | ns | DP | 100% | |||||||
Uschok et al, 201722 | Eclipse | Yes | 14 | 14 | 68.0 | 59–84 | 71 | Poly/MB | DP | 100% | |||||||||
Total | 1564 | 1182 | 382 | 36.1 | 1–127 | 63.8 | 21–90 | 46% | DP 97% AS 3% | 80% | 13% | 2% | 1% | 4% | 3% | 1% |
Note. TSA, total shoulder arthroplasty; HA, hemi-arthroplasty; Poss. COI, possible conflict of interest; mn, month; M/F, male/female ratio; Poly, polyethylene; MB, metal backed; ns, not specified; DP, deltopectoral; AS, anterosuperior; Prim. OA, primary osteoarthritis; Pt. OA, posttraumatic osteoarthritis; ON, osteonecrosis; CTA, cuff tear arthropathy; RA, rheumatoid arthritis; Instab., Instability arthritis; ND, not described.
Posttraumatic OA and ON combined. *Primary and posttraumatic OA combined.